Abstract:e15101 Background: Many proteins, including transcription factors and scaffolding proteins, are not amenable to targeting by traditional small molecule inhibitors due to the lack of a well-defined binding pocket or active site. Proteolysis-Targeting Chimeras (PROTACs) are a new class of hetero-bifunctional molecules that bind both a target protein and an E3 ubiquitin ligase, bringing the two into proximity for appending ubiquitin, and subsequently marking the target protein for proteasomal degradation. Currently, thirteen PROTACs are in clinical trials for oncology indications. However, the clinical utility of PROTACs is challenged by their large size and long development timelines. Also, resistance mutations in the E3 ligase or transporter overexpression inevitably evolve. Thus, a new platform for small-molecule degraders that enables ultra-rapid drug development timelines, efficient cellular uptake, and can be developed to overcome innate and acquired drug resistance is needed. Methods: Coferons, developed in our laboratory, are small molecules that self-assemble upon binding to a target, where they form reversible covalent dimers through bio-orthogonal linker chemistries. We have combined features of the Coferon platform and PROTACs to generate CURE-PROs (Combinatorial Ubiquitination REal-time PROteolysis), consisting of one target protein ligand and one E3 ligase ligand that form reversible heterodimers that lead to targeted protein degradation within cells. By modifying known ligands for BRD4, and the E3 ubiquitin ligases Cereblon, VHL, and MDM2, with linkers able to reversibly join the BRD4 to the ligase ligands, we synthesized libraries of CURE-PRO monomers that can be combined to create thousands of CURE-PRO dimer combinations. We explored whether this platform could yield meaningful BRD4 degradation in vitro and in vivo. Results: Rapid combinatorial cell-based screening identified several BRD4-E3 ligase CURE-PRO combinations that induced greater than 50% BRD4 degradation, with the most promising CURE-PRO pairs achieving more than 95% protein degradation. Consistent with a PROTAC mechanism-of-action, successful CURE-PRO combinations confirmed significant protein degradation which was inhibited by proteasome inhibitors or competition with parent ligands. Significant BRD4 degradation was also observed in mice bearing bilateral human xenograft tumors, confirming CURE-PRO proof-of-mechanism in vivo. Conclusions: The combinatorial nature of our platform has the potential to significantly reduce synthesis time and effort to identify the optimal linker length and E3 ligase for each target protein. The CURE-PRO platform consists of expanding libraries of monomers for both additional oncoprotein targets as well as E3 ligases, which can be redeployed to shorten lead development timelines.

Triple-fusion protein (TRIFU): a potent, targeted, enzyme-like inhibitor of all three complement activation pathways

CG001, a C3b-targeted complement inhibitor blocks three complement pathways: development and preclinical evaluation

C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement

A Novel CRIg‐targeted Complement Inhibitor Protects Cells from Complement Damage

Selection and characterization of a peptide-based complement modulator targeting C1 of the innate immune system

Reconstitution of the alternative pathway of the complement system enables rapid delineation of the mechanism of action of novel inhibitors

Chimeric Proteins Containing MAP-1 and Functional Domains of C4b-Binding Protein Reveal Strong Complement Inhibitory Capacities

Targeted complement inhibition using bispecific antibodies that bind local antigens and endogenous complement regulators

Evolution of Compstatin Family As Therapeutic Complement Inhibitors

Clinical promise of next-generation complement therapeutics

Polymeric Human Fc-fusion Proteins with Modified Effector Functions.

Multivalent Fcγ-receptor engagement by a hexameric Fc-fusion protein triggers Fcγ-receptor internalisation and modulation of Fcγ-receptor functions

Mechanistic insights into complement pathway inhibition by CR1 domain duplication

Proof of concept of a new plasma complement Factor H from waste plasma fraction

Therapeutic targeting of factor D and MASP3 in complement‐mediated diseases: Lessons learned from mouse studies

Co-expression of Human Complement Regulatory Proteins DAF and MCP with an IRES-mediated Dicistronic Mammalian Vector Enhances Their Cell Protective Effects.

Inactivation of Complement by Recombinant Human C3 Derivatives

An Autoimmune Epitope on C-reactive Protein Targets Complement Regulation in Lupus Nephritis

Inhibition of acute complement responses towards bolus-injected nanoparticles using targeted short-circulating regulatory proteins

Co-Expression of the Complement Regulatory Proteins Human Daf and Cd59 with an Ires-Mediated Dicistronic Mammalian Vector Enhances Their Cell Protective Effects

Cure-PROs: Next-generation targeted protein degraders.